Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease

被引:25
作者
Wei, Z.-H. [1 ]
He, Q.-B. [1 ]
Wang, H. [1 ]
Su, B.-H. [1 ]
Chen, H.-Z. [1 ]
机构
[1] Shanghai Jiao Tong Univ, Coll Basic Med Sci, Dept Pharmacol & Biostat, Shanghai 200025, Peoples R China
关键词
Alzheimer's disease; dementia; Cerebrolysin; neurotrophic therapy; clinical trials; meta-analysis;
D O I
10.1007/s00702-007-0630-y
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To determine the therapeutic effect of nootropic agent Cerebrolysin on patients with mild to moderate Alzheimer's disease (AD), we searched the Cochrane Library, Medline, PubMed, and Chinese Biomedical Literature Analysis and Retrieval System for Compact Disc (CBMDISC), and communicated with EBEWE Pharmaceutical Ltd, for randomized trials comparing Cerebrolysin with placebo in AD. Available data on clinical global impression, cognitive performance and activities of daily living were extracted from 6 randomized double-blind placebo-controlled clinical trials and combined with standard meta-analysis methods. An infusion with Cerebrolysin for 4 weeks (30 ml Cerebrolysin daily on five consecutive days of each week) led to a significant improvement of the clinical global impression. Compared with placebo, log(OR) was 1.1799, and 95% confident interval was 0.7463-1.6135 (P < 0.05), indicating that Cerebrolysin could significantly improve the clinical global impression in patients with mild to moderate AD. However, more convincing evidences are needed for the efficacy of Cerebrolysin on the cognitive performance and activities of daily living.
引用
收藏
页码:629 / 634
页数:6
相关论文
共 18 条
  • [1] A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease
    Alvarez, XA
    Cacabelos, R
    Laredo, M
    Couceiro, V
    Sampedro, C
    Varela, M
    Corzo, L
    Fernandez-Novoa, L
    Vargas, M
    Aleixandre, M
    Linares, C
    Granizo, E
    Muresanu, D
    Moessler, H
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (01) : 43 - 54
  • [2] A double-blind, placebo-controlled, multicenter study of cerebrolysin for Alzheimer's disease
    Bae, CY
    Cho, CY
    Cho, K
    Oh, BH
    Choi, KG
    Lee, HS
    Jung, SP
    Kim, DH
    Lee, S
    Choi, GD
    Cho, H
    Lee, H
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (12) : 1566 - 1571
  • [3] Amplification of blood-brain barrier GLUT1 glucose transporter gene expression by brain-derived peptides
    Boado, RJ
    [J]. NEUROSCIENCE RESEARCH, 2001, 40 (04) : 337 - 342
  • [4] Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: An immunohistochemical study on aged rats
    Eder, P
    Reinprecht, I
    Schreiner, E
    Skofitsch, G
    Windisch, M
    [J]. HISTOCHEMICAL JOURNAL, 2001, 33 (11-12): : 605 - 612
  • [5] Frick KM, 1997, J NEUROSCI, V17, P2543
  • [6] Muresanu DF, 2002, J NEURAL TRANSM-SUPP, P277
  • [7] Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO
  • [8] 2-P
  • [9] Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent
    Panisset, M
    Gauthier, S
    Moessler, H
    Windisch, M
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2002, 109 (7-8) : 1089 - 1104
  • [10] Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound Cerebrolysin™
    Rockenstein, E
    Adame, A
    Mante, M
    Larrea, G
    Crews, L
    Windisch, M
    Moessler, H
    Masliah, E
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (02) : 269 - 282